New Insights on the Regulators and Inhibitors of RhoA-ROCK Signalling in Parkinson's Disease

Overview

Journal Metab Brain Dis

Publisher Springer

Specialties Endocrinology
Neurology

Date 2025 Jan 8

PMID 39775342

Authors

Nandita Ravichandran

Mahalaxmi Iyer

Deenathayalan Uvarajan

Laxmi Kirola

Sindduja Muthu Kumra

Harysh Winster Suresh Babu

Dibbanti HariKrishnaReddy

Balachandar Vellingiri

Arul Narayanasamy

Affiliations

Soon will be listed here.

Abstract

A multifaceted and widely prevalent neurodegenerative disease, Parkinson's disease (PD) is typified by the loss of dopaminergic neurons in the midbrain. The discovery of novel treatment(s) that can reverse or halt the course of the disease progression along with identifying the most reliable biomarker(s) in PD remains the crucial concern. RhoA in its active state has been demonstrated to interact with three distinct domains located in the central coiled-coil region of ROCK. RhoA appears to activate effectors most frequently by breaking the intramolecular autoinhibitory connections, which releases functional domains from the effector protein. Additionally, RhoA is highly expressed in the nervous system and it acts as a central molecule for its several downstream effector proteins in multiple signalling pathways both in neurons and glial cells. Mitochondrial dysfunction, vesicle transport malfunction and aggregation of α-Synuclein, a presynaptic neuronal protein genetically and neuropathologically associated with PD. While the RhoA-ROCK signalling pathway appears to have a significant role in PD symptoms, suggesting it could be a promising target for therapeutic interventions. Thus, this review article addresses the potential involvement of the RhoA-ROCK signalling system in the pathophysiology of neurodegenerative illnesses, with an emphasis on its biology and function. We also provide an overview of the state of research on RhoA regulation and its downstream biological activities, focusing on the role of RhoA signalling in neurodegenerative illnesses and the potential benefits of RhoA inhibition as a treatment for neurodegeneration.

References

Ahmed L, Darwish H, Abdelsalam R, Amin H . Role of Rho Kinase Inhibition in the Protective Effect of Fasudil and Simvastatin Against 3-Nitropropionic Acid-Induced Striatal Neurodegeneration and Mitochondrial Dysfunction in Rats. Mol Neurobiol. 2015; 53(6):3927-3938. DOI: 10.1007/s12035-015-9303-2. View

Amano M, Tsumura Y, Taki K, Harada H, Mori K, Nishioka T . A proteomic approach for comprehensively screening substrates of protein kinases such as Rho-kinase. PLoS One. 2010; 5(1):e8704. PMC: 2806833. DOI: 10.1371/journal.pone.0008704. View

Antonescu C, Aguet F, Danuser G, Schmid S . Phosphatidylinositol-(4,5)-bisphosphate regulates clathrin-coated pit initiation, stabilization, and size. Mol Biol Cell. 2011; 22(14):2588-600. PMC: 3135483. DOI: 10.1091/mbc.E11-04-0362. View

Bauer P, Nukina N . Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy. 2009; 5(5):747-8. DOI: 10.4161/auto.5.5.8704. View

Bleckert A, Photowala H, Alford S . Dual pools of actin at presynaptic terminals. J Neurophysiol. 2012; 107(12):3479-92. PMC: 3378406. DOI: 10.1152/jn.00789.2011. View

Brooks S, Dunnett S . Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci. 2009; 10(7):519-29. DOI: 10.1038/nrn2652. View

Cai R, Wang Y, Huang Z, Zou Q, Pu Y, Yu C . Role of RhoA/ROCK signaling in Alzheimer's disease. Behav Brain Res. 2021; 414:113481. DOI: 10.1016/j.bbr.2021.113481. View

Caminiti S, Presotto L, Baroncini D, Garibotto V, Moresco R, Gianolli L . Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. Neuroimage Clin. 2017; 14:734-740. PMC: 5379906. DOI: 10.1016/j.nicl.2017.03.011. View

Cap K, Kim J, Hamza A, Park J . P-Tyr42 RhoA GTPase amplifies superoxide formation through p47phox, phosphorylated by ROCK. Biochem Biophys Res Commun. 2020; 523(4):972-978. DOI: 10.1016/j.bbrc.2020.01.001. View

10.

Cekanaviciute E, Buckwalter M . Astrocytes: Integrative Regulators of Neuroinflammation in Stroke and Other Neurological Diseases. Neurotherapeutics. 2016; 13(4):685-701. PMC: 5081110. DOI: 10.1007/s13311-016-0477-8. View

11.

Chacon P, Garcia-Mejias R, Rodriguez-Tebar A . Inhibition of RhoA GTPase and the subsequent activation of PTP1B protects cultured hippocampal neurons against amyloid β toxicity. Mol Neurodegener. 2011; 6(1):14. PMC: 3038970. DOI: 10.1186/1750-1326-6-14. View

12.

Chen Y, Yang Z, Meng M, Zhao Y, Dong N, Yan H . Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell. 2009; 35(6):841-55. DOI: 10.1016/j.molcel.2009.09.004. View

13.

Chen C, Xiao P, Chen Y, Fang R . Selenium Deficiency Affects Uterine Smooth Muscle Contraction Through Regulation of the RhoA/ROCK Signalling Pathway in Mice. Biol Trace Elem Res. 2019; 192(2):277-286. DOI: 10.1007/s12011-019-01677-8. View

14.

de Almeida A, de Oliveira J, da Silva Pontes L, de Souza Junior J, Goncalves T, Dantas S . ROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways. Oxid Med Cell Longev. 2022; 2022:1225578. PMC: 9605829. DOI: 10.1155/2022/1225578. View

15.

de la Vega M, Burrows J, Johnston J . Ubiquitination: Added complexity in Ras and Rho family GTPase function. Small GTPases. 2011; 2(4):192-201. PMC: 3225908. DOI: 10.4161/sgtp.2.4.16707. View

16.

Deguchi Y, Harada M, Shinohara R, Lazarus M, Cherasse Y, Urade Y . mDia and ROCK Mediate Actin-Dependent Presynaptic Remodeling Regulating Synaptic Efficacy and Anxiety. Cell Rep. 2016; 17(9):2405-2417. DOI: 10.1016/j.celrep.2016.10.088. View

17.

Dorszewska J, Kowalska M, Prendecki M, Piekut T, Kozlowska J, Kozubski W . Oxidative stress factors in Parkinson's disease. Neural Regen Res. 2020; 16(7):1383-1391. PMC: 8284265. DOI: 10.4103/1673-5374.300980. View

18.

Ellerbroek S, Wennerberg K, Burridge K . Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem. 2003; 278(21):19023-31. DOI: 10.1074/jbc.M213066200. View

19.

Fournier A, Takizawa B, Strittmatter S . Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci. 2003; 23(4):1416-23. PMC: 6742251. View

20.

Garcia-Mata R, Boulter E, Burridge K . The 'invisible hand': regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol. 2011; 12(8):493-504. PMC: 3260518. DOI: 10.1038/nrm3153. View